Ozempic Maker Sues US Rival Over Ad Campaign

Novo Nordisk Takes Legal Action Against Eli Lilly Over Advertising Claims

Kabarsaji.com – Danish pharmaceutical leader Novo Nordisk has initiated legal proceedings against American competitor Eli Lilly, alleging deceptive marketing practices. The lawsuit, filed on Tuesday in a New Jersey federal district court, centers on accusations that Eli Lilly’s promotional materials contain false and misleading information.

According to Novo Nordisk, the American company has deliberately chosen outdated research studies for its advertising campaigns. These studies compare elevated doses of Novo Nordisk’s GLP-1 agonist medications—Wegovy and Ozempic—against reduced doses of Eli Lilly’s Mounjaro and Zepbound products.

“The American firm’s ads are deceptively (presented) those results as proof of broad, product-level superiority while burying or omitting critical clinical context,” the Danish group said.

The legal action cites violations of both fair competition regulations and federal false advertising statutes. Novo Nordisk contends that Eli Lilly’s promotional campaign reached millions of viewers through global sporting event broadcasts, as well as social media platforms including TikTok and Facebook, resulting in significant public misunderstanding.

John F. Kuckelman, the company’s general counsel, emphasized the importance of transparency for consumers: “As new and more effective treatment options become available, people deserve accurate information that reflects the latest scientific evidence and helps them make informed care decisions.”

Understanding GLP-1 Medications

GLP-1 medications function by replicating the body’s naturally occurring GLP-1 hormone, which is generated following meals and plays a crucial role in appetite regulation. Both Novo Nordisk and Eli Lilly have independently created synthetic versions of this hormone for therapeutic use.

These medications serve dual purposes: treating type 2 diabetes and facilitating weight loss. The growing popularity of their weight management applications has generated substantial financial benefits for both pharmaceutical corporations.

Read: Tate Brothers to Fight Extradition to UK, Says Lawyer

Click here to get the latest news updates from Tempo on Google News